EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer

Madison L Conces iD, Amit Mahipal iD

Current Oncology · 2024

DOI: 10.3390/curroncol31010024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2024. Verfasst von Madison L Conces und 1 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Rectal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Local and metastatic recurrence are primary concerns following the treatment of locally advanced rectal cancer (LARC). Chemoradiation (CRT) can reduce the local recurrence rates and has subsequently moved to the neoadjuvant setting from the adjuvant setting. Pathological complete response (pCR) rates have also been noted to be greater in patients treated with neoadjuvant CRT prior to surgery. The standard approach to treating LARC would often involve CRT followed by surgery and optional adjuvant chemotherapy and remained the treatment paradigm for almost two decades. However, patients were often unable to complete adjuvant chemotherapy due to a decreased tolerance of chemotherapy following surgery, which led to upfront treatment with both CRT and chemotherapy, and total neoadjuvant therapy, or TNT, was created. The efficacy outcomes of local recurrence, disease-free survival, and pCR have improved in patients receiving TNT compared to the standard approach. Additionally, more recent data suggest a possible improvement in overall survival as well. Patients with a complete clinical response following TNT have the opportunity for watch-and-wait surveillance, allowing some patients to undergo organ preservation. Here, we discuss the clinical trials and studies that led to the adoption of TNT as the standard of care for LARC, with the possibility of watch-and-wait surveillance for patients achieving complete responses. We also review the possibility of overtreating some patients with LARC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Second PrimaryRectal NeoplasmsHumansNeoadjuvant TherapyChemoradiotherapyChemotherapy, AdjuvantDisease-Free SurvivalPathologic Complete Response

Stichwörter der Autor:innen

chemotherapyneoadjuvant therapyrectal cancer

Autor:innen und Institutionen

  • University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.

ORCID-Profile: Madison L Conces, Amit Mahipal

Zitieren

APA

Conces, M. L., & Mahipal, A. (2024). Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer. Current Oncology. https://doi.org/10.3390/curroncol31010024

Vancouver

Conces ML, Mahipal A. Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer. Current Oncology. 2024. doi:10.3390/curroncol31010024

BibTeX
@article{Conces2024,
  author = {Conces, Madison L and Mahipal, Amit},
  title = {Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31010024}
}
Kostenlos starten →